Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…Abstract Number: 1570 • 2019 ACR/ARP Annual Meeting
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Background/Purpose: : In a related study, we have shown evidence to support the validity of the Automated Neuropsychological Assessment Metrics (ANAM) for the screening of…Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…Abstract Number: 1572 • 2019 ACR/ARP Annual Meeting
Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors
Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE) and its course may change over time. The objective was to determine…Abstract Number: 1573 • 2019 ACR/ARP Annual Meeting
Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort
Background/Purpose: The prevalence of atherosclerotic vascular events (AVE) in published literature of an inception cohort with SLE is 10%. We aimed to investigate the accrual…Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…Abstract Number: 1576 • 2019 ACR/ARP Annual Meeting
Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis
Background/Purpose: To characterize the frequency of thrombocytopenia in SLE and determine its time of onset during the course of the disease, severity and impact on mortality.Methods: This…Abstract Number: 1577 • 2019 ACR/ARP Annual Meeting
The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus
Background/Purpose: The 2017 guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) define hypertension at a threshold of ≥130/80mmHg for the systolic and diastolic…Abstract Number: 1578 • 2019 ACR/ARP Annual Meeting
Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus
Background/Purpose: Osteonecrosis (ON) complicates approximately 15-20% of patients with systemic lupus erythematosus (SLE) on an average of six years after diagnosis. However, a small subgroup…Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting
Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race
Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…Abstract Number: 1580 • 2019 ACR/ARP Annual Meeting
Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Background/Purpose: Development of comorbidity over time in patients with systemic lupus erythematosus (SLE) is not well characterized. To provide a detailed and comprehensive picture hereof,…Abstract Number: 1581 • 2019 ACR/ARP Annual Meeting
Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Background/Purpose: Risk of end stage renal disease (ESRD) is increased in patients with systemic lupus erythematosus (SLE). Due to lifestyle –related risk factors, inflammation, and…Abstract Number: 1582 • 2019 ACR/ARP Annual Meeting
The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is associated with an increased incidence of venous thromboembolism (VTE). Lupus nephritis (LN) has…Abstract Number: 1583 • 2019 ACR/ARP Annual Meeting
Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus
Background/Purpose: Background: There is an increasing knowledge about the utility of urinary biomarkers for the diagnosis of lupus nephritis (LN) in patients with systemic lupus…
- « Previous Page
- 1
- …
- 861
- 862
- 863
- 864
- 865
- …
- 2425
- Next Page »